160296-41-3

Basic information

• Product Name: Tert-Butyl 4-((4-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate
• Synonyms: Tert-Butyl 4-((4-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate
• CAS NO: 160296-41-3
• Molecular Formula: C₁₇H₂₄FNO₃
• Molecular Weight: 309.38
• Mol File: 160296-41-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Tert-Butyl 4-((4-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Tert-Butyl 4-((4-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate(160296-41-3)
• EPA Substance Registry System: Tert-Butyl 4-((4-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate(160296-41-3)

Safety Data

• Hazardous Substances Data: 160296-41-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Tert-Butyl 4-((4-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate is used as an intermediate in the synthesis of various organic compounds. Its unique structure and functional groups make it a versatile building block for the development of new molecules with potential applications in various industries.
Used in Pharmaceutical Research:
Tert-Butyl 4-((4-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate is used as a starting material or a key intermediate in the development of new pharmaceuticals. Its potential biological activity and the presence of various functional groups make it a promising candidate for the design and synthesis of novel drug molecules.
Used in Medicinal Chemistry Research:
Tert-Butyl 4-((4-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate is used as a valuable tool in medicinal chemistry research. Its unique structure and functional groups allow researchers to explore its potential as a lead compound for the development of new therapeutic agents.
Used in Chemical Reactions:
Tert-Butyl 4-((4-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate is used as a reactant in various chemical reactions. Its functional groups, such as the hydroxy and methyl groups attached to the 4-fluorophenyl ring, enable it to participate in a wide range of chemical transformations, making it a useful compound for the synthesis of new molecules with potential applications in different fields.

Upstream product

• 160296-40-2 tert-butyl 1-[4-(4-fluorobenzoyl)piperidin-1-yl]carboxylate 
• 56346-57-7 (4-fluorophenyl)-piperidin-4-ylmethanone 
• 25519-77-1 1-(4-(4-fluorobenzoyl)piperidin-1-yl)ethanone 
• 59084-16-1 1-acetylpiperidine-4-carbonyl chloride 
• 25503-90-6 1-acetyl-piperidine-4-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 

Downstream Products

• 160296-42-4 tert-butyl 4-((4-fluorophenyl)(methoxy)methyl)piperidine-1-carboxylate 
• 160296-43-5 4-[1-(4-fluorophenyl)-1-methoxymethyl]piperidine 
• 160296-40-2 tert-butyl 1-[4-(4-fluorobenzoyl)piperidin-1-yl]carboxylate 
• 1598371-28-8 ethyl 4-(4-(4-fluorobenzoyl)piperidin-1-yl)butanoate 
• 58113-21-6 4-[(4-fluorophenyl)phenylmethylene]piperidine 
• 56346-57-7 (4-fluorophenyl)-piperidin-4-ylmethanone 
• 123855-52-7 tert-butyl 4-[(4-fluorophenyl)methoxymethyl]piperidine-1-carboxylate 

Relevant articles and documents

Development of Fluorine-18 Labeled Metabolically Activated Tracers for Imaging of Drug Efflux Transporters with Positron Emission Tomography

Increased activity of efflux transporters, e.g., P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), at the blood-brain barrier is a pathological hallmark of many neurological diseases, and the resulting multiple drug resistance represents a major clinical challenge. Noninvasive imaging of transporter activity can help to clarify the underlying mechanisms of drug resistance and facilitate diagnosis, patient stratification, and treatment monitoring. We have developed a metabolically activated radiotracer for functional imaging of P-gp/BCRP activity with positron emission tomography (PET). In preclinical studies, the tracer showed excellent initial brain uptake and clean conversion to the desired metabolite, although at a sluggish rate. Blocking with P-gp/BCRP modulators led to increased levels of brain radioactivity; however, dynamic PET did not show differential clearance rates between treatment and control groups. Our results provide proof-of-concept for development of prodrug tracers for imaging of P-gp/BCRP function in vivo but also highlight some challenges associated with this strategy.

OXIME COMPOUNDS AND THE USE THEREOF

The invention relates to oxime compounds of Formula (I) and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein X is hydrogen, optionally substituted aryl, optionally substituted heteroaryl or the like; Y is CO, SO2, CRsu

Syntheses and Binding Studies of New [(Aryl)(aryloxy)methyl]piperidine Derivatives and Related Compounds as Potential Antidepressant Drugs with High Affinity for Serotonin (5-HT) and Norepinephrine (NE) Transporters

In a wide search program toward new, efficient, and fast-acting antidepressant drugs, we have prepared series of new compounds having an (aryl)(aryloxy)methyl moiety linked directly or through a methylene chain to different substituted and unsubstituted cycles (isoquinoline, piperazine, piperidine, tetrahydropyran, or cyclopentane). These compounds have been evaluated for their affinities for serotonin (5-HT) transporter (SERT) and 5-HT1A and 5-HT2A receptors. Racemic mixtures of 4-[(aryl)(aryloxy)methyl]piperidine derivatives showed much higher affinity values for SERT than fluoxetine and resulted in lack of affinity for 5-HT 1A and 5-HT2A receptors. Some of these racemic mixtures were resolved to their enantiomers and tested for binding to norepinephrine (NE) transporter (NET), dopamine (DA) transporter (DAT), and α2 receptor. Several of these enantiomers [(-)-15b, (-)-15j, (-)-15t, (+)-15u] displayed a dual binding profile with affinities for SERT and NET with K i i = 1.9 and 13.5 nM, respectively), and further pharmacological characterization is in progress for its evaluation as a antidepressant.

7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics

Compound 1 (1-benzyl-3-methyl-4-[4-(4-fluorophenyl)-4- oxobutyl]piperazine), a synthetic intermediate identified as a potential atypical antipsychotic, was selected as the starting point for pharmacological improvement. From 1, sequential structural variations were conducted in order to improve its potency and oral bioavailability. These variations included a series of piperazine, ethanediamine, and piperidine derivatives. The piperidine series afforded some orally potent compounds in the inhibition of apomorphine-induced climbing and hyperactivity in mice, which are regarded as behavioral models predictive of antipsychotic efficacy. Further optimization of these structures led to the highly potent 7-[3-(1- piperidinyl)propoxy]chromenones. Inhibition of stereotypies and induction of catalepsy in rats at doses substantially higher than required for inhibition of climbing suggest an atypical antipsychotic profile, which is assumed to predict a reduced induction of extrapyramidal side effects in humans.